Daniel Antier

665 total citations
47 papers, 539 citations indexed

About

Daniel Antier is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel Antier has authored 47 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Pediatrics, Perinatology and Child Health and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel Antier's work include Heme Oxygenase-1 and Carbon Monoxide (7 papers), Neuroscience of respiration and sleep (6 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Daniel Antier is often cited by papers focused on Heme Oxygenase-1 and Carbon Monoxide (7 papers), Neuroscience of respiration and sleep (6 papers) and Pharmaceutical Practices and Patient Outcomes (5 papers). Daniel Antier collaborates with scholars based in France, United States and Switzerland. Daniel Antier's co-authors include Gaël Y. Rochefort, Sylvie Chalon, Claire Tronel, Véronique Eder, Sylvie Bodard, Nicolas Arlicot, Jean-Marc Hyvelin, Pierre Bonnet, Guylène Page and Marie‐Christine Machet and has published in prestigious journals such as PEDIATRICS, Brain Research and Neuroscience.

In The Last Decade

Daniel Antier

45 papers receiving 525 citations

Peers

Countries citing papers authored by Daniel Antier

Since Specialization

Citations

This map shows the geographic impact of Daniel Antier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Antier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Antier more than expected).

Fields of papers citing papers by Daniel Antier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Antier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Antier. The network helps show where Daniel Antier may publish in the future.

Co-authorship network of co-authors of Daniel Antier

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Antier. A scholar is included among the top collaborators of Daniel Antier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Antier. Daniel Antier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brain, CSF, and Blood Metabolomics Signature in the TgF344-AD Rat Model of Alzheimer’s Disease 2025 ·Journal of Proteome Research ·(unknown), Sylvie Mavel, Kelly Ceyzériat, Sylvie Chalon, Lydie Nadal‐Desbarats, Sylvie Bodard, Antoine Lefèvre, (unknown), (unknown), Daniel Antier, (unknown), Patrick Emond, Benjamin B. Tournier, (unknown)	0
2	Why is there no biosimilar of Erbitux®? 2023 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Valentina D’Atri, Davy Guillarme, Daniel Antier, (unknown), Alain Beck, Hervé Watier, (unknown)	8
3	Compared benefits of educational programs dedicated to diabetic patients with or without community pharmacist involvement 2020 ·Primary Health Care Research & Development ·(unknown), (unknown), (unknown), (unknown), Daniel Antier	2
4	Reassessment of inappropriate prescriptions of proton pump inhibitors in elderly in-patients: It's time to take action 2020 ·Annales Pharmaceutiques Françaises ·(unknown), Adrien Bigot, F. Maillot, Daniel Antier, (unknown)	5
5	Alpha-7 nicotinic acetylcholine receptor agonist treatment in a rat model of Huntington's disease and involvement of heme oxygenase-1 2018 ·Neural Regeneration Research ·(unknown), Claire Tronel, Sylvie Bodard, (unknown), (unknown), Sylvie Chalon, Daniel Antier	15
6	Neuroprotective effect of the alpha 7 nicotinic receptor agonist PHA 543613 in an in vivo excitotoxic adult rat model 2017 ·Neuroscience ·(unknown), (unknown), Guylène Page, (unknown), Patrick Emond, Nuno F. Rodrigues, Frédéric Dollé, (unknown), Frédéric Buron, Sylvain Routier, Sylvie Chalon, Daniel Antier	28
7	A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids 2013 ·Journal of Pharmaceutical and Biomedical Analysis ·Renaud Respaud, (unknown), (unknown), Jean‐François Tournamille, Emmanuel Gyan, Daniel Antier, Marie‐Claude Viaud‐Massuard	8
8	Heme Oxygenase-1 Inducer Hemin Attenuates the Progression of Remnant Kidney Model 2009 ·Nephron Experimental Nephrology ·(unknown), Jean-Marc Hyvelin, Marie‐Christine Machet, Véronique Eder, (unknown), Jean‐Michel Halimi, Daniel Antier	17
9	Short- and Long-Term Cardioprotective Effect of Darbepoetin-α: Role of Bcl-2 Family Proteins 2009 ·Journal of Cardiovascular Pharmacology ·(unknown), Daniel Antier, Marie‐Christine Machet, Jean-Marc Hyvelin	12
10	Intravascular ultrasound allows a hyperplasia diagnosis in vivo in rat as accurate as histomorphometry 2008 ·Ultrasonics ·Gaël Y. Rochefort, (unknown), Marie‐Christine Machet, Jean‐Michel Halimi, Véronique Eder, Daniel Antier	1
11	EFFECT OF THE HEME OXYGENASE INDUCER HEMIN ON BLOOD HAEMOSTASIS MEASURED BY HIGH‐FREQUENCY ULTRASOUND 2007 ·Clinical and Experimental Pharmacology and Physiology ·Gaël Y. Rochefort, (unknown), (unknown), (unknown), Jean‐Michel Halimi, F. Ossant, Véronique Eder, Daniel Antier	2
12	Are Antibiotic Drugs Well Prescribed in Case of Renal Insufficiency? A Retrospective Study 2007 ·Renal Failure ·Nicolas Arlicot, Xavier Pourrat, (unknown), (unknown), Daniel Antier	4
13	Traitement des surinfections bronchiques: stabilité des antibiotiques dans les diffuseurs portatifs 2006 ·Therapies ·(unknown), Fabien Lamoureux, Xavier Pourrat, (unknown), Sophie Marchand, (unknown), Daniel Antier	7
14	Exercise and Vasorelaxing Effects of CO-Releasing Molecules in Hypertensive Rats 2006 ·Medicine & Science in Sports & Exercise ·Julien Boissière, (unknown), Daniel Antier, Daniel Courteix, Pierre Bonnet	12
15	Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension 2006 ·European Journal of Pharmacology ·Gaël Y. Rochefort, (unknown), Véronique Eder, G. Hanton, Jean-Marc Hyvelin, Pierre Bonnet, Daniel Antier	12
16	Validation et mise en place d'un nouveau programme de contrôle-qualité des cytotoxiques reconstitués en unité centralisée 2002 ·Journal de Pharmacie Clinique ·(unknown), Daniel Antier, (unknown), (unknown)	2
17	New program for quality control of cytotoxics manufactured in centralised unit 2002 ·Journal de Pharmacie Clinique ·Susan Watt, Daniel Antier, (unknown), (unknown)	5
18	Idazoxan does not prevent but worsens focal hypoxic-ischemic brain damage in neonatal Wistar rats 1999 ·Journal of Neuroscience Research ·Daniel Antier, Florence Franconi, (unknown)	8
19	Effects of neonatal focal cerebral hypoxia–ischemia on sleep–waking pattern, ECoG power spectra and locomotor activity in the adult rat 1998 ·Brain Research ·Daniel Antier, (unknown), François Mailliet, Serge Akoka, (unknown), (unknown)	8
20	L'étude des flux et des stocks 1957 ·Daniel Antier, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact